To whom it may concern

Company: Teijin Limited
Stock code: 3401 (First Section, Tokyo Stock Exchange)
Representative: Jun Suzuki, President and CEO
Contact: Hiroki Sorate, General Manager, Investor Relations Department
Tel: +81-3-3506-4395

Issuance of Notification on the Extension of the Reexamination Period for the Hyperuricemia and Gout Treatment FEBURIC® (febuxostat)

Tokyo, Japan, September 7, 2018 --- Teijin Limited announced today that a notification on the extension of the reexamination period for the hyperuricemia and gout treatment FEBURIC® (febuxostat) of Teijin Pharma Limited, a subsidiary of Teijin, was issued on September 4 by the Director of the Pharmaceutical Evaluation Division, Pharmaceutical Health and Safety Bureau, Ministry of Health, Labour and Welfare. Details are as follows.

Name of pharmaceutical: FEBURIC Tablet 10 mg, FEBURIC Tablet 20 mg, FEBURIC Tablet 40 mg
Extended reexamination period: Until January 20, 2021
Holder of approval: Teijin Pharma Limited
Reasons: It was recognized that there is a need to implement trials to set the dosage and administration for pediatric patients and assess efficacy and safety in the pediatric population.

This matter will have a negligible impact on the consolidated full-term operating results forecasts for the fiscal year ending March 31, 2019.